Clinical Scorecard: Review of Accelerated Cancer Treatment Approvals: A Cross-Sectional Study in China from 2005 to 2021
At a Glance
Category
Detail
Condition
Malignant hematology and oncology cancers
Key Mechanisms
Expedited regulatory approval programs including Special Approval, Special Review, Priority Review, Conditional Approval, and Breakthrough Therapy to accelerate access to novel cancer therapies
Target Population
Cancer patients in China requiring innovative therapies for life-threatening or rare conditions
Care Setting
Oncology clinical care and drug regulatory approval settings in China
Key Highlights
China has the highest global cancer incidence and mortality, necessitating accelerated access to innovative cancer treatments.
China’s Expedited Approval (EA) programs evolved from Special Approval in 2005 to include Priority Review and Conditional Approval pathways aligned with FDA and EMA standards by 2020.
Conditional Approval allows earlier drug approval based on surrogate endpoints but requires confirmatory trials to verify clinical benefit, with potential for withdrawal if benefits are not confirmed.
Guideline-Based Recommendations
Diagnosis
Identify cancer patients with unmet medical needs or life-threatening conditions eligible for expedited drug access.
Management
Utilize EA programs to facilitate earlier access to promising oncology drugs based on surrogate endpoints or less comprehensive clinical data.
Monitor ongoing confirmatory trials post-Conditional Approval to ensure clinical benefit.
Monitoring & Follow-up
Track review timelines and clinical trial outcomes to assess the impact of EA programs on drug approval speed and therapeutic value.
Evaluate clinical benefits of approved drugs using validated scales such as ESMO-MCBS.
Risks
Potential withdrawal or indication revocation if confirmatory trials fail to verify anticipated clinical benefits under Conditional Approval.
Patient & Prescribing Data
Patients with malignant hematology and oncology indications in China receiving drugs approved via EA programs from 2005 to 2021.
EA programs have enabled earlier patient access to novel cancer therapies, with pivotal trials often relying on surrogate endpoints; ongoing evaluation of clinical benefit is essential.
Clinical Best Practices
Leverage expedited regulatory pathways to reduce drug development and review timelines for oncology therapies addressing urgent medical needs.
Incorporate early communication and rolling review processes to streamline drug approval.
Use surrogate endpoints judiciously to support Conditional Approval while ensuring robust post-marketing confirmatory studies.
Align national expedited approval programs with international standards to facilitate global harmonization and patient access.
